Dr. Daniel Konrad - Statement about the CardioExcyte 96

   “Impedance and field potential data of beating cardiomyocytes is getting increasingly important to obtain a comprehensive view of the cardiac liability of test compounds. To answer these questions for our clients, B’SYS successfully implemented the CardioExcyte 96 system and provides related validated services to its customers, mostly using ipS derived cardiomyocytes. B’SYS’ scientists are pleased with the CardioExcyte’s ease of operation and data acquisition. The powerful software allows for applying meaningful data analysis and time saving export of data as needed for our daily customer reports.“

Dr. Daniel Konrad
CEO B'SYS